AlgoRx Pharmaceuticals Inc. intends to use proceeds from its $65 million Series C financing to bankroll ongoing development of its two lead Phase II drug candidates. (BioWorld Today)
Biogen Idec Inc. and partner Elan Corp. plc gained value Wednesday after telling Wall Street they intend to file the Antegren application for multiple sclerosis based on one-year data, as opposed to waiting for the traditional two-year data set to be completed. (BioWorld Today)
The FDA gave Antigenics Inc. the go-ahead to resume enrollment of two Phase III trials for the personalized cancer vaccine Oncophage, following a 13-week partial clinical hold. (BioWorld Today)
WASHINGTON - Medicare legislation poised for a vote in Congress contains language designed to get generics to market faster by closing loopholes in a law that has enabled certain innovator pharmaceutical companies to block generic competition. (BioWorld Today)
